Selective stimulation of colonic L cells improves metabolic outcomes in mice
Open Access
- 27 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetologia
- Vol. 63 (7), 1396-1407
- https://doi.org/10.1007/s00125-020-05149-w
Abstract
Aims/hypothesis Insulin-like peptide-5 (INSL5) is found only in distal colonic L cells, which co-express glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). GLP-1 is a well-known insulin secretagogue, and GLP-1 and PYY are anorexigenic, whereas INSL5 is considered orexigenic. We aimed to clarify the metabolic impact of selective stimulation of distal colonic L cells in mice. Methods Insl5 promoter-driven expression of Gq-coupled Designer Receptor Exclusively Activated by Designer Drugs (DREADD) was employed to activate distal colonic L cells (LdistalDq). IPGTT and food intake were assessed with and without DREADD activation. Results LdistalDq cell stimulation with clozapine N-oxide (CNO; 0.3 mg/kg i.p.) increased plasma GLP-1 and PYY (2.67- and 3.31-fold, respectively); INSL5 was not measurable in plasma but was co-secreted with GLP-1 and PYY in vitro. IPGTT (2 g/kg body weight) revealed significantly improved glucose tolerance following CNO injection. CNO-treated mice also exhibited reduced food intake and body weight after 24 h, and increased defecation, the latter being sensitive to 5-hydroxytryptamine (5-HT) receptor 3 inhibition. Pre-treatment with a GLP1 receptor-blocking antibody neutralised the CNO-dependent improvement in glucose tolerance but did not affect the reduction in food intake, and an independent group of animals pair-fed to the CNO-treatment group demonstrated attenuated weight loss. Pre-treatment with JNJ-31020028, a neuropeptide Y receptor type 2 antagonist, abolished the CNO-dependent effect on food intake. Assessment of whole body physiology in metabolic cages revealed LdistalDq cell stimulation increased energy expenditure and increased activity. Acute CNO-induced food intake and glucose homeostasis outcomes were maintained after 2 weeks on a high-fat diet. Conclusions/interpretation This proof-of-concept study demonstrates that selective distal colonic L cell stimulation has beneficial metabolic outcomes. Graphical abstractKeywords
Funding Information
- Biotechnology and Biological Sciences Research Council
- Wellcome Trust (106263/Z/14/Z)
- Medical Research Council (MRC_MC_UU_12012/3)
This publication has 53 references indexed in Scilit:
- Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretionDiabetologia, 2012
- Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein–Coupled Receptor FFAR2Diabetes, 2012
- Na+-d-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin SecretionDiabetes, 2011
- Endogenous peptide YY and neuropeptide Y inhibit colonic ion transport, contractility and transit differentially via Y1 and Y2 receptorsBritish Journal of Pharmacology, 2011
- Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodentsInternational Journal of Obesity, 2010
- Glucose Sensing in L Cells: A Primary Cell StudyCell Metabolism, 2008
- The Physiology of Glucagon-like Peptide 1Physiological Reviews, 2007
- 5-Hydroxytryptophan activates colonic myenteric neurons and propulsive motor function through 5-HT4receptors in conscious miceAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2007
- Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetesRegulatory Peptides, 2004
- The involvement of 5-HT3 and 5-HT4 receptors in two models of gastrointestinal transit in miceNeuroscience Letters, 2002